메뉴 건너뛰기




Volumn 1, Issue 1, 2011, Pages 14-16

A new BATTLE in the evolving war on cancer

Author keywords

[No Author keywords available]

Indexed keywords

BEXAROTENE; BIOLOGICAL MARKER; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; PROTEIN TYROSINE KINASE INHIBITOR; SORAFENIB; VANDETANIB;

EID: 80055033886     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8274.CD-11-0044     Document Type: Article
Times cited : (11)

References (15)
  • 3
    • 74949133978 scopus 로고    scopus 로고
    • American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer
    • Azzoli CG, Baker S Jr, Temin S, Pao W, Aliff T, Brahmer J, et al. American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 2009;27:6251-66.
    • (2009) J Clin Oncol , vol.27 , pp. 6251-6266
    • Azzoli, C.G.1    Baker Jr., S.2    Temin, S.3    Pao, W.4    Aliff, T.5    Brahmer, J.6
  • 5
    • 24944497744 scopus 로고    scopus 로고
    • Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib
    • Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005;23:5900-9.
    • (2005) J Clin Oncol , vol.23 , pp. 5900-5909
    • Eberhard, D.A.1    Johnson, B.E.2    Amler, L.C.3    Goddard, A.D.4    Heldens, S.L.5    Herbst, R.S.6
  • 7
    • 33847666453 scopus 로고    scopus 로고
    • Practical Bayesian adaptive randomisation in clinical trials
    • Thall PF, Wathen JK. Practical Bayesian adaptive randomisation in clinical trials. Eur J Cancer 2007;43:859-66.
    • (2007) Eur J Cancer , vol.43 , pp. 859-866
    • Thall, P.F.1    Wathen, J.K.2
  • 8
    • 38649094549 scopus 로고    scopus 로고
    • Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: Results from Southwest Oncology Group randomized trials
    • Lara PN Jr, Redman MW, Kelly K, Edelman MJ, Williamson SK, Crowley JJ, et al. Disease control rate at 8 weeks predicts clinical benefit in advanced non-small-cell lung cancer: results from Southwest Oncology Group randomized trials. J Clin Oncol 2008;26:463-7.
    • (2008) J Clin Oncol , vol.26 , pp. 463-467
    • Lara Jr., P.N.1    Redman, M.W.2    Kelly, K.3    Edelman, M.J.4    Williamson, S.K.5    Crowley, J.J.6
  • 9
    • 34249810645 scopus 로고    scopus 로고
    • KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer
    • Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res 2007;13:2890-6.
    • (2007) Clin Cancer Res , vol.13 , pp. 2890-2896
    • Massarelli, E.1    Varella-Garcia, M.2    Tang, X.3    Xavier, A.C.4    Ozburn, N.C.5    Liu, D.D.6
  • 10
    • 69349088824 scopus 로고    scopus 로고
    • Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: Results of an online tumor registry of clinical trials
    • Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, et al. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res 2009;15:5267-73.
    • (2009) Clin Cancer Res , vol.15 , pp. 5267-5273
    • Jackman, D.M.1    Miller, V.A.2    Cioffredi, L.A.3    Yeap, B.Y.4    Jänne, P.A.5    Riely, G.J.6
  • 11
    • 70349720358 scopus 로고    scopus 로고
    • Biomarker analyses from a phase III, randomized, open-label, firstline study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS)
    • abstract 8006
    • Fukuoka M, Wu Y, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Biomarker analyses from a phase III, randomized, open-label, firstline study of gefitinib (G) versus carboplatin/paclitaxel (C/P) in clinically selected patients (pts) with advanced non-small cell lung cancer (NSCLC) in Asia (IPASS). J Clin Oncol 2009;27 Suppl: abstract 8006.
    • (2009) J Clin Oncol , vol.27 , Issue.SUPPL.
    • Fukuoka, M.1    Wu, Y.2    Thongprasert, S.3    Yang, C.H.4    Chu, D.T.5    Saijo, N.6
  • 12
    • 34547638047 scopus 로고    scopus 로고
    • Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer
    • Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
    • (2007) Nature , vol.448 , pp. 561-566
    • Soda, M.1    Choi, Y.L.2    Enomoto, M.3    Takada, S.4    Yamashita, Y.5    Ishikawa, S.6
  • 13
    • 79951885125 scopus 로고    scopus 로고
    • Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer
    • Sequist LV, Gettinger S, Senzer NN, Martins RG, Jänne PA, Lilenbaum R, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol 2010;28:4953-60.
    • (2010) J Clin Oncol , vol.28 , pp. 4953-4960
    • Sequist, L.V.1    Gettinger, S.2    Senzer, N.N.3    Martins, R.G.4    Jänne, P.A.5    Lilenbaum, R.6
  • 14
    • 79551709894 scopus 로고    scopus 로고
    • Final results from ARQ 197-209: A global randomized placebocontrolled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC)
    • Paper presented at; October 8-11, Milan, Italy
    • Sequist LV, Akerley W, Brugger W, Ferrari D, Garmey EG, Gerber DE, et al. Final results from ARQ 197-209: a global randomized placebocontrolled phase 2 clinical trial of erlotinib plus ARQ 197 versus erlotinib plus placebo in previously treated EGFR-inhibitor naïve patients with advanced non-small cell lung cancer (NSCLC). Paper presented at European Society for Medical Oncology Congress; October 8-11, 2010; Milan, Italy.
    • (2010) European Society for Medical Oncology Congress
    • Sequist, L.V.1    Akerley, W.2    Brugger, W.3    Ferrari, D.4    Garmey, E.G.5    Gerber, D.E.6
  • 15
    • 78650509347 scopus 로고    scopus 로고
    • Randomized, phase II, multicenter, doubleblind, placebo-controlled study evaluating MetMAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer (OAM4558g)
    • Paper presented at; October 8-11, Milan, Italy
    • Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Krzakowski M, et al. Randomized, phase II, multicenter, doubleblind, placebo-controlled study evaluating MetMAb, an antibody to Met receptor, in combination with erlotinib, in patients with advanced non-small-cell lung cancer (OAM4558g). Paper presented at European Society for Medical Oncology Congress; October 8-11, 2010; Milan, Italy.
    • (2010) European Society for Medical Oncology Congress
    • Spigel, D.R.1    Ervin, T.J.2    Ramlau, R.3    Daniel, D.B.4    Goldschmidt, J.H.5    Krzakowski, M.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.